Duchenne Muscular Dystrophy (DMD) clinical trials in Pennsylvania
11 active Duchenne Muscular Dystrophy (DMD) trials with a site in Pennsylvania. Describe your situation to see which ones look like a fit.
- A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
- Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
- DMD Voice: Qualitative Interviews With Patients and Caregivers
- Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
- Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
- Biomarker Development for Muscular Dystrophies
- Urinary Titin Biomarker in DMD
- A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
- A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
- An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.